GLPwatch

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.

Pharmacol Res · 2022

Last updated 2026-05-28

Research suggests GLP-1 receptor agonists (GLP-1RAs), already used to lower blood sugar and aid weight loss, may also reduce inflammation and influence the immune system. Studies in cells and animals show these drugs can target different pathways in various tissues, indicating they have wide-ranging effects beyond their current approved uses.

AI summary of the abstract below.

JournalPharmacol Res, 2022
Citations292
Relative citation ratio27.54
NIH percentile100
Molecules

Abstract

In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP-1RAs have anti-inflammatory properties and that may modulate the immune-system. Notably, such anti-inflammatory effects target different pathways in different tissues, underling the broad spectrum of GLP-1RAs actions. This review examines some of the currently proposed molecular mechanisms of GLP-1RAs actions and explores their potential benefits in reducing inflammatory responses, which may well suggest a future therapeutic use of GLP-1RAs in new indications.

Verbatim abstract via PubMed 35738455 ↗